showed a trendP =0.08
Both edoxaban doses demonstrated noninferiority to VKA in reducing the risk of stroke or SE in the primary analysis, including patients in the intent-to-treat population who received study drug during the treatment period (annual rates of 1.61%, 1.18%, and 1.50% for low-dose edoxaban, high-dose edoxaban, and warfarin, respectively); high-dose edoxaban showed a trend toward better efficacy vs warfarin in a prespecified superiority analysis of the intent-to-treat population during the entire study period (1.57% vs 1.80%; P =0.08). 29 In Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), 18,201 patients (mean CHADS 2 score 2.1; median age 70 years) were randomized to apixaban 5 mg twice daily (2.5 mg doses were used in patients with two or more of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine level ≥1.5 mg/dL) or warfarin.